Pesquisar
GH Research PLC
GHRSAdicionar à lista de desejos
28.070USD
-0.310-1.09%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
1.92BValor de mercado
PerdaP/L TTM
Mais detalhes de GH Research PLC Empresa
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Informações de GH Research PLC
Código da empresaGHRS
Nome da EmpresaGH Research PLC
Data de listagemJun 25, 2021
CEOValcheva (Velichka)
Número de funcionários50
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
EndereçoJoshua Dawson House
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 RY95
Telefone35314378334
Site
Código da empresaGHRS
Data de listagemJun 25, 2021
CEOValcheva (Velichka)
Executivos da empresa GH Research PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de GH Research PLC?
Os cinco principais acionistas de GH Research PLC são: Mr. Florian Schonharting
Quantas instituições possuem ações da GH Research PLC (GHRS)?
Em 2026Q1, 109 instituições possuíam ações da GH Research PLC, com valor de mercado aproximado de 46.87M, representando 68.37% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3238705.00.